ctDNA detection after LBCL therapy predicts 97% vs 29% progression-free survival, superior to PET scans for determining true remission status.
Fourth cohort receiving 30x initial dose with no dose-limiting toxicities observed to date.
FDA grants de novo authorization to ArteraAI Prostate, first AI tool to prognosticate long-term outcomes in localized prostate cancer.
IMvigor011 trial shows Signatera ctDNA test predicts which bladder cancer patients benefit from adjuvant atezolizumab immunotherapy.
FDA grants Breakthrough Therapy Designation to izalontamab brengitecan for previously treated EGFR-mutated NSCLC patients.
FDA grants breakthrough therapy designation to ifinatamab deruxtecan for pretreated extensive-stage small cell lung cancer patients.
